Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL9 | O00512 | 7/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 7/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18152351 | 1.00 | BCL9 (0.43) | BCL9CTNNB1PIK3CDHSD11B1CYP2C9 | |
| SCHEMBL18165166 | 0.86 | PIK3CD (0.50) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL21062542 | 0.82 | BCL9 (0.45) | BCL9CTNNB1EPHX2 | |
| SCHEMBL21062541 | 0.82 | BCL9 (0.45) | BCL9CTNNB1EPHX2 | |
| SCHEMBL23456262 | 0.82 | BCL9 (0.62) | BCL9CTNNB1 | |
| SCHEMBL23456260 | 0.82 | BCL9 (0.62) | BCL9CTNNB1 | |
| SCHEMBL20021957 | 0.78 | ALOX5AP (0.47) | BCL9CTNNB1 | |
| SCHEMBL23456198 | 0.76 | BCL9 (0.51) | BCL9CTNNB1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL23456310 | 0.76 | PIK3CD (0.49) | BCL9CTNNB1PIK3CDPIK3CAPIK3CB | |
| SCHEMBL18165167 | 0.76 | PIK3CD (0.49) | BCL9CTNNB1PIK3CDPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016168524-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2016-10-20 | — | — | WO | disclosed |